A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
증례보고
1/5 보강
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alp
APA
Li T, Wu BL, et al. (2026). A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.. Clinical case reports, 14(2), e72025. https://doi.org/10.1002/ccr3.72025
MLA
Li T, et al.. "A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.." Clinical case reports, vol. 14, no. 2, 2026, pp. e72025.
PMID
41669704
Abstract
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure. By analyzing the course of treatment and regression, the risks and management strategies of combining immune checkpoint inhibitors (ICIs) with immunomodulators are discussed in the light of the literature. This highlights the need for clinical vigilance against possible immune overactivation triggered by combination therapy.
같은 제1저자의 인용 많은 논문 (5)
- Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy.
- Engineered internal architecture of core-shell lipid nanoparticles promotes efficient mRNA endosomal release.
- ERRγ impedes neuroendocrine prostate cancer development.
- ASO Visual Abstract: Oxidative Stress Inflammation Score is the Optimal Inflammatory Prognostic Indicator for Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy: A Multicenter Retrospective Cohort Study.
- Research Progress on Nano-Drug Delivery Systems for Photothermal Cancer Therapy.